The massive undertaking reported in Wetmore et al. (2012) represents an important step forward as we integrate innovative in vitro chemical screening efforts such as ToxCast into risk assessment approaches. However, the authors overstate the degree to which their exposure estimates represent the "highest estimated U.S. population exposures" and consequently underestimate the number of chemicals for which current exposures exceed levels associated with biological activity.
The massive undertaking reported in Wetmore et al. (2012) represents an important step forward as we integrate innovative in vitro chemical screening efforts such as ToxCast into risk assessment approaches. However, the authors overstate the degree to which their exposure estimates represent the "highest estimated U.S. population exposures" and consequently underestimate the number of chemicals for which current exposures exceed levels associated with biological activity.
In this study, the researchers estimated human oral doses expected to produce steady-state blood concentrations at which ToxCast chemicals were active in vitro. They then compared these "active" doses with estimates of human exposure that they characterized as the "highest estimated U.S. population exposures" and the "estimated upper limit of human exposure." These estimates came primarily not only from pesticide registration documents but also from exposure surveillance data in National Health and Nutrition Examination Survey (NHANES). The authors attempted to capture higher exposures of susceptible subpopulations by selecting the 95th percentile estimates from subgroups presented in the Centers for Disease Control (CDC) exposure report (2009) and characterized these exposures as representing "most highly exposed subpopulations" in Figure 4B and the study abstract.
However, 95th percentile estimates of NHANES subpopulations defined by age, gender, and ethnicity do not capture extreme variability in the high end of exposure distributions. In publicly available NHANES data, it is not unusual for maximum values to exceed 95th percentiles by a factor of 100 or more. For example, maximum values of several pesticides, chlorinated solvents, mercury, and several phthalates are more than 100 times higher than 95th percentile values in NHANES data cycles from 1999 to 2010, and one 8-year-old girl in the 2007-2008 test had urinary mono-n-butyl phthalate levels almost 900 times higher than the 95th percentile (NCHS/CDC, 2012). NHANES is designed to be a representative sample of the 300 million-person U.S. population, and so the top 5% of NHANES exposures represent over 15 million people. NHANES data clearly demonstrate that "upper limits of human exposure" are well above 95th percentile levels and may reflect exposure to sizable subgroups. Thus, the highest exposures cannot necessarily be considered rare events and have broad public health significance.
We appreciate Wetmore's acknowledging the need for better population exposure data. Most of the exposure estimates used in this screening came from EPA pesticide Reregistration Eligibility Decision (RED) documents which have not been validated against NHANES and other biomonitoring data. RED exposure estimates, which are intended to represent "high end" exposure, should be systematically evaluated as in some cases exposure estimates from REDs may underestimate these values. For example, the diazinon RED exposure estimate does not consider cancelled uses, such as residential exposure, even though diazinon is still detected in homes, so exposure from former residential uses continues. Although Wetmore et al. (2012) validated RED estimates with NHANES 95th percentiles for triclosan and cacodylic acid, these may not be representative. For these two chemicals, there is better exposure data than for most; for example, the triclosan RED appears to have relied on NHANES data in its derivation, whereas most chemicals do not.
For chemicals with limited exposure data, it is important to use available data and to clarify that without exposure data there is no basis for reassurance that exposure levels are below activity levels. No estimate of human exposure was included for 24% of the chemicals in the study, and so no comparison toxicological sciences 128(1), 295-296 (2012) doi:10.1093/toxsci/kfs143 Advance Access publication April 20, 2012 was made between estimated doses associated with activity and current exposures. Among these 57 chemicals, NHANES biomonitoring data are available for several, including atrazine, lindane, and PFOA, and it is unclear why these data were not used to represent population exposures. Highlighting data gaps provides incentive to generate the needed information and avoids false reassurance, which is especially important in this article and other screening-level assessments.
Although several other limitations are acknowledged by the authors, we are concerned that the article understates the impact of these limitations. The study abstract and conclusions convey a sense that the study represents a "worst-case" screening exercise, but the study's limitations are likely to result in underestimates of population exposures and risks. For example:
• Modeling of doses expected to lead to blood concentrations with activity did not adequately consider sources of interindividual variation such as age, genetics, and health conditions because variability in the model was based on "interindividual variability in a population of 100 healthy individuals of both sexes from 20 to 50 years of age." • In vitro bioactivity assays generally do not capture activity caused by metabolites of the tested chemical.
• In vitro assay active concentration values (LEC and AC50s) may be above minimum levels required to induce biological activity.
• The IVIVE model underpredicted steady-state blood concentrations for PFOA and PFOS by roughly a factor of 100 among 13 chemicals that were included in a validation subset. The suitability of this model for screening assessments should be carefully considered.
Identifying chemicals for which population exposure exceeds levels causing biological activity is an essential goal of screeninglevel assessments. Thus, it is important that exposure estimates reflect the extreme variation in environmental exposure data, including values above the 95th percentile, and come from validated models where possible. Furthermore, researchers should highlight data gaps and methodological limitations throughout the analysis and evaluate their impacts on study conclusions.
